Australia was one of the first countries to introduce a publicly funded HPV vaccine program, and its introduction coincided with a media campaign to promote regular cervical screening. One issue with HPV vaccination is how it impacts on demand for screening. This study examines changes in women's screening preferences following these two interventions, using a novel approach to policy evaluation based on repeated discrete choice experiments.
these factors to shape future screening behaviour. For example, Gerard et al. (2003) use SP data to analyse determinants of breast screening participation and find that, while attributes of the screening are important, women's participation decisions are also affected by factors such as the manner in which they were informed about screening and the screening environment offered by the health provider which can be policy targets.
In our study, the identification of the effects of the interventions will be achieved through comparisons of outcomes of the 'treated' and 'control' groups, in the standard sense that only the former was exposed to any intervention. The availability of an identical DCE conducted in 2004, before both interventions were introduced (DCE1), provides one control group, allowing us to compare the preferences before and after the policy interventions. In addition, several other control groups are formed through spatial variations and randomisation in the follow-up DCE collected after both interventions (DCE2). These extra comparison groups are useful to isolate out any common (time) trend effect.
The existing literature predicts that awareness would increase women's willingness to be screened (Fernbach, 2001; Marcus and Crane, 1998; Jenkins et al., 1999; Mullins et al., 2008) . A previous screening promotion campaign in New South Wales, for instance, recorded a 30% increase in screening uptake within 4 months of the promotion campaign (Shelley et al., 1991) .
However, never before has a screening promotion campaign been implemented at the same time as a vaccination program, another means to prevent cervical cancer. It could be hypothesised that the two interventions could support one another, but alternatively, the vaccination program could also counteract the effectiveness of the screening campaign, for example due to misconceptions that vaccination can substitute for screening (Newall et al. 2007 ; Kulasingam and Myers, 2003) . This study will provide the first results in relation to these issues.
Background
Cervical cancer is a cancer of the cervix. The cancer develops when women are infected with high-risk strains of HPV (13-18 strains) for a number of years. As the progression of the cancer to an invasive state is slow (up to 10 years) and pre-invasive stages are largely asymptomatic, regular screening is crucial. Early detection of abnormal cells is known to have high curative rates. In Australia, the current recommendation is for women to begin screening between the age of 18 and 21, or a year after commencing sexual activity, whichever is later, and continue two yearly screening until the age of 70.
For the past 40 years, the Pap test has been the main means of cervical screening, but recently alternative tests have been developed, most recently a HPV test to detect specifically high-risk strains of HPV. When used in conjunction with a Pap test, this test is almost 100% accurate. A Pap test alone is typically about 50-85% accurate (Salmeron et al., 2003; Wright et al., 2000) . In Australia, women would not typically be offered the choice of a HPV test unless they first had a positive Pap test.
The causal link between HPV infection and cervical cancer has led to development of HPV vaccines to prevent an initial HPV infection. The first vaccine to receive marketing approval ad government funding in Australia was Gardasil, which targets HPV types 16 and 18 which together cause 70% of cervical cancer and HPV types 6 and 11 which cause an estimated 90% of cases of genital warts. Being vaccinated does not exempt women from screening because the vaccine does not protect against other high-risk strains of HPV or eliminate existing exposure to HPV. The vaccine is therefore most effective when received prior to sexual debut.
Discrete Choice Experiments
While DCEs have previously been used in a policy evaluation context, a novelty of this study is a methodological one demonstrating the use of repeated DCEs conducted before and after a policy intervention.
A DCE is one stated-preference (SP) method of producing behavioural data that asks its respondents (subjects) for their preferred choice, as opposed to observing their actual decisions in real market situations (which fits a type of revealed-preference (RP) data). The behavioural foundation of SP methods is Lancastrian consumer theory, which proposes a decomposition of utility derived from the consumption of a product into the utilities derived from its attributes. Hence, in a DCE, the product of interest is described by its attributes and their associated levels, which jointly set a scenario. Studies have found that although stated choices are made in a hypothetical setting, in which there is no real consequence of making the choice, one goes through a similar decision making process as in the real market setting (Louviere et al., 2000; Telser and Zweifel, 2007) .
The DCEs in this study contain the screening determinants and test options.
The first DCE (DCE1) was developed by Fiebig et al. (2009 Fiebig et al. ( ) in 2004 to quantify the role of these screening factors in women's screening decisions. In June 2007, after both government interventions were introduced, the experiment was rerun (DCE2). The content of the DCEs is described below.
A scenario is described by a combination of alternative-specific attributes, which reflect the characteristics of a given test, and common or context attributes, which aim to capture the environment in which the screening decision has to be made. Common attributes are fixed across alternatives. The combination of common and alternative-specific attributes produces over 16 million (4 4 x 2 4 x 4 3 x 2 ) possible scenarios. Experimental design techniques are as described in Burgess and Street (2004a, 2004b) and Fiebig et al. (2009) are used to reduce the potential scenarios to a manageable fraction, while retaining the ability to identify the utility weight of each attribute independently of each other. the respondent i will choose j over l if:
The presence of the random component ε in (2) makes it a probabilistic statement. The probability that the alternative j is chosen over the other possible alternatives therefore can be written as:
For the deterministic component, let and ij ω that would follow a yet-to-be specified distribution and induce heteroskedasticity and correlation over alternatives. Notice that ij ω varies over respondents, but is fixed over repeated scenarios faced by a respondent, thereby inducing serial correlation across scenarios.
The assumption of additive error term implies that the main source of heterogeneity is inherent taste heterogeneity among women. Some variations however may be related to a particular attribute, and the error component (2010) to allow for alternative sources of heterogeneities is left for future study. However, as we will see later, our results suggest that the role of taste heterogeneity is dominant.
The normal distribution is used for (6) reflecting that there are people who tend to choose a given alternative, and there are others who tend not to prefer it. The location of the mean will suggest the prevalence of each kind of preferences.
Under the normality assumption, the choice probability in the MXL model is a mixture of logits with a multivariate normal mixing distribution.
Conditional on the random parameters, the probability will follow the standard logit specification. However, as respondent's taste is unobserved, the unconditional probability is an integral of the conditional probabilities over all possible values of the random parameters, weighted by its probability density function. This problem has no closed-form solution and is approximated numerically through simulation by:
where j, l = P, L, PH, LH, r indexes a particular draw and R is the total number of draws. As only differences in utilities matter, the no test alternative is chosen as the base with an associated utility of zero.
The mean of these simulated probabilities is then taken to the objective function to be maximised by Maximum Likelihood. Halton draws are used in the simulation instead of random draws to increase the accuracy of estimation. The random intercepts are allowed to be freely correlated with each other; implying that Ω in (6) is given by:
Treated and control groups
To identify the effects of the interventions on screening choice and utility weights, we need definitions of the treated group, which has been affected by the interventions, and the control group. The DCE1 respondents are a clear control group, as this survey was collected pre-interventions. However, relying on time variation has the limitation of not knowing the extent of each woman's exposure to the interventions; there is no information in the survey, for example, about women's awareness of the screening promotion advertisement. In the extreme case, it is possible that all women in DCE2 are unaware of both the screening promotion materials and the vaccination program, making them fit the definition of a control group. To deal with this problem, several other definitions for the treated and control groups are proposed. There are 4 cases in total, which are summarised in Table 2. [Insert Table 2 The MXL model is estimated independently for treated and control samples.
By doing so, we can test if samples have different scales (the overall extent of unobserved heterogeneity). In discrete choice models, the scale factor is confounded by the utility parameters. However, the identification of the scale factor is desirable, as a larger scale implies a lower variance of the unobservables, which may result from increased awareness. Furthermore, from a policy point of view, different policy strategies are appropriate if women have the same response patterns with respect to choice attributes, but one group of women is more variable in its behaviour than others, from those that are appropriate in the situation in which the underlying behavioural parameters have genuinely changed after the interventions.
Results

Screening choice responses
Respondents for the survey were a stratified random sample of women living in New South Wales aged 18-69 who had previously had a Pap test. Each experiment involves a different sample. DCE1 consists of 167 previouslyscreened women. As each respondent provided responses to 32 scenarios, there are 5,344 respondent-scenarios. In DCE2, there are 154 previouslyscreened women to make a total of 4,928 respondent-scenarios. However, one respondent is dropped because she is over 70 years of age and cervical screening is no longer recommended for women in this age group and 25 respondent-scenarios are dropped due to multiple responses in a given scenario. Compared to women in DCE1, women in DCE2 tend to be younger, more educated, born overseas and have higher incomes (Johar et al., 2009 ).
We control for these differences in the estimation.
The distribution of responses is reported in Table 3 . In all cases, the shares of women who chose no test are shown to be higher in the treated than in the control samples. The difference is statistically significant in Case 1 and 4, which both involve comparison against pre-treatment period. This pattern is inconsistent with the prior expectation that awareness would motivate screening participation. Investigating further, this overall increase in non participation is found to be driven by young women's choices. For instance, in DCE1, the share of women under 20 who chose no test was 26%, while in DCE2, this group of women has 55% non-participation rate. This age-specific phenomenon thus hints that the drop in participation rate is related to the parallel vaccination program, which is targeted to these young women. For instance, they may falsely believe that vaccination and screening are alternative strategies to prevent cervical cancer, and that getting vaccinated can substitute for screening. If so, the vaccination program actually counteracts some of the effect of the screening promotion campaign, rather than working together with it to achieve the common goal of cervical cancer prevention. Meanwhile, the share of a given test alternative is on average stable between a pair of comparison samples.
[Insert Table 3 about here]
Preference and attribute values
The MXL models are estimated using the routine by Hole (2007) Table 4 reports the results for Case 1. First considering the random intercepts, in the treated sample (DCE2), all the mean intercepts are negative and statistically significant, predicting that in given a scenario, the reference women in the sample (i.e., young women with low education and income, born in Australia, and who were never smokers) would tend to choose not to be tested. On the other hand, the reference women in the control sample (DCE1) are indifferent between no test and a standard Pap test. The location of each of the mean intercepts in DCE2 is further to the left from its counterpart in DCE1, suggesting results that are consistent with the raw data discussed earlier, that the joint interventions have generated negative preferences towards testing in general.
1 However, the interventions seem to reduce the extent of heterogeneity surrounding a given test alternative. The standard deviations around the means are all large and significant, but are slightly smaller in magnitude in DCE2. Moreover, these deviations are not always larger than their respective means, which is the case in DCE1.
Meanwhile, both samples exhibit significant correlation in pairwise alternatives, except between P and LH. This exception is sensible, as serial correlation is personal, and women who have a taste for technology would be most likely to choose a liquid-based Pap test over the standard Pap test.
[Insert Table 4 about here]
Next, to compare attribute parameters from the two samples, Figure 1A plots the set of estimates from DCE2 against those obtained from DCE1. In non-linear models, this device isolates differences in scales (overall variance) from genuine differences in utility weights; coefficient estimates from different samples are not directly comparable due to confounded scales, which can be sample-specific. Scaling phenomenon implies a systematic difference between the parameter estimates from different samples, with estimates from the sample exhibiting a larger scale being scaled down. On a scatter plot of treated sample against control sample, these estimates will have a linear relationship with slope steeper than a 45-1 One can find the probability of getting a value less than 0 of a normally distributed random variable with mean and standard deviation equal to the MXL estimates for each alternative. For instance, for a standard Pap test the probability of getting a value less than 0 of a normally distributed random variable with mean 1.5 and standard deviation 2.5 is 0.73 in DCE2.
degrees line. Meanwhile, points above the 45-degree line indicate larger estimates in the treated sample.
[Insert Figure 1 about here]
For the attributes, the plot shows that the differences in utility weights are largely systematic. While there is no obvious reason why women should change their valuations of screening attributes following the interventions, one can imagine that awareness of screening importance reduces the weights on costs and/or increases the weights on accuracy. The results however suggest that screening participation has always been highly influenced by provider characteristics and recommendation, and costs and test accuracy received unchanging weights.
The different coding system for attributes and the socio-demographic variables turns out to be important, as the effects of socio-demographics, unlike the attributes' weights, vary with samples. Although most of them are not statistically significant, the reversing sign of the coefficients on education and smoking variables to positive is noteworthy. That is, in DCE2, higher education increases the propensity to test, and smokers and ex-smokers are more likely to test than non-smokers. The changing behaviour related to smoking habits in particular is a positive outcome from the perspective of women's health, as smoking increases the risk of developing cervical cancer.
The coefficient on ex-smokers is statistically significant at the 5% level. 
Eligibility for free Gardasil
Whether it is the parallel vaccination program in particular that creates the aversion towards testing can be checked by removing young women (under 30 years old), who are eligible for the vaccination program, from the DCE2
sample. This restriction reduces the sample by nearly half. Table 5 shows that now all test means are statistically indifferent from zero, suggesting that the targeted vaccination program that occurs at the same time as the screening promotion is a part of the story. Meanwhile the results regarding the screening attributes are largely consistent with those obtained from the unrestricted sample; the correlation coefficient between them is 0.98.
As additional information on the test preference of older women, the restriction was also imposed on DCE1. We find that all test mean intercepts are negative and significant. Variations around the means are substantial in any case, but that for the joint liquid-based Pap and HPV test alternative is considerably smaller in size in the DCE2 sample.
[Insert Table 5 about here]
To sum up, despite the screening promotion effort, the majority of women (still) prefer not to be screened. Spatial comparisons suggest that this is due to a reduction in the taste for screening related to HPV events. Meanwhile, the values of screening attributes to a typical woman and the overall scale, which one may interpret as measuring the extent of uncertainty surrounding screening decision-making in general, appear to be independent of any intervention. The policy implication following these results is therefore for future screening promotion effort to integrate the HPV innovations. In particular, the relationship between cervical cancer, screening, HPV facts, and HPV-based measures must be communicated in an orderly fashion to avoid confusion and prevent women from making false self-assessments of their risk of developing the cancer. Better delivery of information may also reduce the uncertainties surrounding the screening decision.
Policy simulations
Given the significant role of providers in women's screening decisions, stimulating their involvements seems to be a plausible strategy to boost screening rates. Using the attributes related to the GP in the experiment, simulation is used to forecast the impact of this strategy. As alternative strategies, let us consider a price reduction, which is the common policy instrument to increase demand and an investment in Research and Development (R&D) that produces a more accurate Pap test. Currently, the standard Pap test is covered by Medicare, but the newer tests would involve positive out-of-pocket costs.
Consider the case for a representative woman who is on-time for screening (the last test occurred within 2 years). To reflect reality, we specify recommended screening interval at 2 years. Other attributes are selected so that the predicted screening rate in DCE1 for 20-69 years old is consistent with the actual two-year participation rate for these groups of women according to the Australian Institute of Health and Welfare's (AIHW) report, which is 58% in 2003 -2004 (AIHW, 2008 . The corresponding market share for 2007 onwards is not (yet) available. This alignment requires the GP to be specified as male and as the regular GP of the women. The HPV test costs $50, and is not recommended. With regards to test accuracy, we set the false positive and negative rates at 1% and a 20%, respectively
The 'price effect' ( 1 E ), 'provider effect' ( 2 E ) and 'R&D effect' ( 3 E ) to screening participation are found as follows:
( )
where N is the sample size, and iNT P is the individual average of the probability of no test (NT) alternative from 100 draws, drawn from their estimated distributions. The parameters are given by the MXL estimates. The superscript H ( L ) denotes the case in which screening was recommended without the test type specified and the liquid-based Pap test costs an additional $40 ($10), superscript P ( NR ) denotes the case in which the GP recommended the standard Pap test (not recommending testing), and superscript A denotes the case in which the accuracy of the standard Pap increases to a 0.1% false positive rate and a 5% false negative rate. The R&D effect is found using the probability of no test under the low price case,
as the reference point. Within-sample variations are achieved by the random draws as well as variations in socio-demographics characteristics. Table 6 reports the results for (9) - (11). For the extent of the policy change considered, all of the three policies have considerable effects on the screening rate. The price subsidisation can reduce the non-participation rate by around 20% in most samples. Meanwhile, by encouraging health providers to take a more active role in screening promotion (perhaps, in women's visits for other purposes), the non-participation rate can be reduced by 40 to 50%. A large provider effect is indeed not impractical (Myers et al., 2008) . R&D spending on technology research has a similar-size effect to the provider effect, but arguably, the R&D returns take longer. For an immediate impact, the government therefore may consider the price strategy, although a generous subsidy (in the above case 75% of the costs) may be needed for large effects, and/or extending incentives for opportunistic screening (e.g., amending the current Practice Improvement Program (PIP)). For the longer run effect, resources can be allocated to R&D that improves test accuracy.
[Insert Table 6 about here]
Conclusion
This study has analysed changes in women's attitudes towards cervical screening following the latest (2007) screening promotion campaign and a parallel vaccination program providing HPV vaccine, Gardasil, in Australia.
The successes of previous screening promotion campaigns and other preventive health campaigns (e.g., the SunSmart program in Victoria state, Australia, which aims to lower skin cancer rate) led to the expectation that the promotion campaign would substantially increase the cervical screening rate.
However, it is found that the proportion of women willing to be screened is generally lower after the joint interventions. This trend is unexpected, but at least in Australia, there is no precedent for concurrently running a screening promotion campaign and a vaccination program.
The reduction in the participation rate appears to be associated with HPV events. First, the reduction in willingness-to-screen is particularly marked among young women, who can obtain Gardasil for free under the vaccination program. Meanwhile, there is little evidence that given individual characteristics, the older women are averse towards testing. These results therefore suggest that while screening and vaccination are both preventive means for cervical cancer, the effectiveness of the screening promotion effort Through a simulation exercise, several potential strategies to increase future screening rates were evaluated, and the result suggests that encouraging a more active role of health providers is the most effective strategy among those considered to achieve this goal, capable of reducing the nonparticipation rate by close to one half. Meanwhile, R&D spending on technology that improves test accuracy can be justified on the basis of its expected sizeable impact on screening participation in the longer term. Note: * indicates difference with control group is statistically significant at 1% level based on two-mean sample comparison test. The sample size is the number of respondents * 32 scenarios. In DCE2, the sample excludes the 70 year old women and multiple responses as described in Section 5.1. Note: Reported under Coeff column are MXL coefficients, and under p column is the probability value that the respective coefficient is equal to zero. Coefficients without probability values are coefficients of the reference group. 'Rec' stands for GP's recommendation. For standard Pap, the cost levels are $0, $10, $20 and $30, and the costs of liquid-based test add to these cost. For false positive (FP) and false negative (FN) rates, the first figure is for standard Pap and the second is for liquid-based test. * pvalues of the covariance terms. The number of draws for the simulated probabilities is R = 2,000. Note: The number of replication for simulated probabilities are R=1000. * p-values based on covariance terms. Only 25 percent of DCE1 sample are aged less than 30. The number of women in the restricted sample is 81. Results for unrestricted case DCE2 are reported in Table 4 . 
